A 24-week randomized, double-blind, placebo-controlled trial investigated the effect of silymarin on liver stiffness in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Eighty-three participants were divided between a silymarin group (103.2 mg/day) and a placebo group. Results showed that silymarin significantly reduced liver stiffness, γ-glutamyl transpeptidase (GGT), and ApoB levels compared to placebo. However, it did not significantly affect hepatic steatosis or other biochemical and physical parameters. Gut microbiota analysis revealed increased diversity, particularly an enrichment of Oscillospiraceae, suggesting a potential role of microbiota modulation in silymarin’s effects on liver health.
Home » Silymarin Reduces Liver Stiffness in MASLD Patients by Modulating Gut Microbiota: A 24-Week Randomized Controlled Trial
Silymarin Reduces Liver Stiffness in MASLD Patients by Modulating Gut Microbiota: A 24-Week Randomized Controlled Trial
Facebook
Twitter
LinkedIn
Email
WhatsApp
Facebook
Twitter
LinkedIn
Email
WhatsApp
Related Shorts
Dietary Zinc Could Lower Endometriosis Risk
November 2, 2024
Grape Seed Extract for Mood Regulation and Cognitive Health
October 24, 2024
Menthol : A Novel Therapeutic Pathway for Alzheimer’s
October 24, 2024
Vitamin D and Probiotics: A New Strategy for Managing Migraines
October 18, 2024
Spermidine: The Polyamine with Potential for a Healthier Heart!
October 18, 2024